Orthopaedic patients remain among those most affected by NHS waiting lists in 2026, with tens of thousands waiting for knee and hip replacement surgery and many more facing lengthy delays for shoulder, spinal and ACL procedures. This NHS backlog update examines the latest waiting list data, treatment volumes and private healthcare costs, while exploring why increasing numbers of UK patients are considering self-pay treatment and accredited European hospitals as alternatives to long waits and rising private sector prices.

For orthopaedic patients across the UK, the NHS backlog remains one of the most significant barriers to timely treatment in 2026. Behind the national waiting list figures are patients living with pain, reduced mobility, lost income and declining independence while waiting for procedures that can transform quality of life.

Orthopaedics is particularly exposed because many of the highest-demand procedures are elective, high-volume and life-improving rather than immediately life-saving. That means patients can wait months, sometimes far longer, before receiving treatment. For someone unable to walk comfortably, work normally or sleep without pain, the word “elective” does not reflect the reality of daily life.

The clearest example is total knee replacement. Knee replacement surgery remains one of the highest-volume elective procedures in the UK, with 49,509 patients currently on NHS waiting lists and an average waiting time of approximately 28.7 weeks. In 2025, the NHS performed 79,196 knee replacement procedures, equal to 6,599 per month. The private sector performed slightly more, with 80,055 procedures annually, or 6,671 per month. That balance is striking. It shows that private capacity is no longer marginal. It is already carrying a volume of knee replacement activity comparable to the NHS.

Cost, however, remains a major barrier. UK private knee replacement surgery costs between £13,149 and £15,117. By comparison, the average EU cost is approximately £8,825, around 32 percent lower. For self-pay patients who cannot wait 29 weeks but cannot easily absorb UK private hospital prices, this gap matters.

Hip replacement surgery shows a similar pattern. There are currently 31,323 patients waiting for hip replacement on NHS lists, with an average waiting time again around 28.7 weeks. The NHS performed 103,805 hip replacement procedures in 2025, equivalent to 8,650 per month, while the private sector carried out 65,771 procedures annually, or 5,480 per month.

Hip replacement is one of the most successful procedures in modern medicine, but delayed access can have serious consequences. Patients often deteriorate while waiting. Reduced mobility leads to muscle loss, loss of confidence, weight gain and increased dependence on family members. UK private hip replacement costs between £12,549 and £14,950, while the average EU cost is approximately £9,088, around 27 percent lower. Again, the issue is not simply waiting time or price in isolation. It is the combination of long waits, rising pain and a UK private price point that remains unaffordable for many households.

Shoulder replacement is a smaller category, but it remains highly relevant. There is no reliable NHS waiting list count available for this treatment, but typical waits range from 20 to more than 30 weeks depending on the trust. In 2025, the NHS performed 9,558 shoulder replacement procedures, around 796 per month. The private sector performed 3,290 annually, or 274 per month.

Although the volume is lower than knee or hip replacement, the impact can still be severe. Shoulder arthritis and joint damage can affect sleep, dressing, washing, driving and work. UK private shoulder replacement costs between £12,149 and £13,752. The average EU cost is approximately £8,804, around 27 percent lower. For patients facing months of pain and restricted function, cross-border treatment can offer a faster and more affordable route.

Spinal surgery presents a different but equally important opportunity. There is no clear NHS waiting list count or average waiting time available for this category, but the total procedure volume was around 65,594 per year in 2023 across NHS and private activity, equivalent to approximately 5,466 per month. Private discectomy in the UK costs approximately £11,305, compared with an average EU cost of around £6,994, approximately 38 percent lower.

This is one of the sharpest price differentials across the core MMG orthopaedic categories. It is also a category where urgency and lifestyle impact can drive strong patient motivation. Back and leg pain caused by disc problems can affect younger and working-age patients, disrupting employment, family life and physical activity. For many, waiting is not a passive inconvenience. It is an active deterioration in daily life.

ACL reconstruction is another important entry point, particularly among younger and more active patients. There is no national NHS waiting list count available, but typical elective waits of 40 to 60 weeks are seen in many trusts. Annual UK procedure volume is estimated at between 14,000 and 21,600 across NHS and private care, or around 1,200 to 1,800 per month. UK private ACL reconstruction costs approximately £7,040, compared with an average EU cost of approximately £6,217, around 12 percent lower.

The price gap is smaller than for joint replacement or spinal surgery, but the motivation can be just as strong. ACL injuries affect sport, work, confidence and long-term knee stability. For younger patients, a year-long wait can mean a lost season, reduced fitness and a prolonged inability to return to normal activity.

Across these five procedures, the same pattern is visible. NHS waiting times remain long. UK private treatment remains expensive. Accredited European hospitals offer lower-cost capacity for patients who want consultant-led care without waiting months for treatment.

This is the structural opportunity facing UK orthopaedic patients in 2026. The NHS continues to deliver enormous volumes of care, but demand remains too high for many patients to access treatment quickly. The UK private sector offers speed, but often at prices many self-pay patients cannot afford. MMG accredited European hospitals provide a third route: faster access, high-quality treatment and more competitive pricing.

For MMG, the conclusion is clear. Orthopaedic patients need more than reassurance that they are on a list. They need practical access to treatment. They need transparent pricing, accredited providers and a pathway that allows them to compare options based on quality, cost and location.

In 2026, the NHS backlog is not just a system problem. It is a patient problem. For tens of thousands of people waiting for knee, hip, shoulder, spinal or ACL surgery, the real question is no longer whether delays exist. It is how long they are prepared to live with them.